https://orcid.org/0000-0002-8186-2926
References
- Cornwell CR, Hsu J, Tompkins LK, Pennington AF, Flanders WD, Sircar K. Clinical outcomes among hospitalized US adults with asthma or chronic obstructive pulmonary disease, with or without COVID-19. J Asthma. 2021:1–11. doi:10.1080/02770903.2021.2018703.
- Signes-Costa J, Núñez-Gil I, Soriano J, Arroyo-Espliguero R, Eid CM, Romero R, Uribarri A, Fernández-Rozas I, Aguado MG, Becerra-Muñoz VM, et al. Prevalence and 30-day mortality in hospitalized patients with Covid-19 and prior lung diseases. Arch Bronconeumol. 2021;57:13–20. doi:10.1016/j.arbres.2020.11.012.
- Kotagiri P, Mescia F, Hanson A, Turner L, Bergamaschi L, Peñalver A, Richoz N, Moore S, Ortmann B, Dunmore B, Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration, et al. The impact of hypoxia on B cells in COVID-19. EBioMedicine. 2022;77:103878. doi:10.1016/j.ebiom.2022.103878.
- Hernandez AM, Holodick NE. Editorial: natural antibodies in health and disease. Front Immunol. 2017;8:1795.
- Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, Muccini C, Monti G, De Luca G, Landoni G, COVID-BioB study group, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2021;27(3):451–457. doi:10.1016/j.cmi.2020.10.021.
- Brouqui P, Amrane S, Million M, Cortaredona S, Parola P, Lagier J-C, Raoult D. Asymptomatic hypoxia in COVID-19 is associated with poor outcome. Int J Infect Dis. 2021;102:233–238. doi:10.1016/j.ijid.2020.10.067.